We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Cerecor Inc. (neurology and respiratory therapeutics) raised $6.8mm through its Series A-1 preferred stock financing to 146 undisclosed investors. The company will use the funds to complete the technology transfer of CERC301 (a Phase II-ready selective NR2B antagonist for depression) and the COMT platform from Merck & Co. Inc. Cerecor has raised $30mm since its 2011 inception.
Deal Industry
Biotechnology
Pharmaceuticals
Pharmaceuticals
Specialty Pharmaceuticals
Deal Status
Final
Deal Type
Financing
Venture Financing
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?